 
 
 
 
COVID -19 Outpatient Pragmatic Platform Study (COPPS):  
A pragmatic multi -arm, adaptive, phase 2, blinded, randomized placebo-
controlled platform trial to assess the efficacy of different investigational 
therapeutics in reducing time to disease resolution or viral load cessation, 
as compared to standard supportive care in outpatients with COVID -19 
Study Protocol and Statistical Analysis Plan  
[STUDY_ID_REMOVED]  
September 21, 2021 
COPPS   V9 | 20210921 
 
Confidential   Page 1 of 51  
 
COVID -19 Outpatient Pragmatic Platform Study (COPPS):  
A pragmatic multi -arm, adaptive, phase 2, blinded, randomized placebo -
controlled platform trial to assess the efficacy of different investigational 
therapeutics in reducing time to disease resolution or viral load cessation, as 
compared to standard support ive care in outpatients with COVID -19 
  
  
Document History  Notes  
Version 1       Date: 06 October  2020  Initial Approval  
Version 2       Date: 17 November 2020  PIND recommendations  
Version 3       Date: 11 December 2020  Second PIND recommendation  
Version 4       Date: 29 January 2021  Ops language, Inclusion, & viral endpoint  
Version 5       Date: 09 March 2021  New viral endpoint, clinical missing data  
Version 6       Date: 30 March 2021  Ops language, alignment of visits  
Version 7       Date: 04 May 2021  Updated blind, schedule of events, DSMB  
Version 8       Date: 07 Jul 2021  Monoclonal antibody (MAB) EUA criteria  
Version 9       Date: 21 September  
2021  Updated assessment schedule  
 
 
SUMMARY OF CHANGES FROM VERSION 8 TO V ERSION 9  
 
• Updated schedule of assessments 
• Changed Visit 10 from in- person to telehealth visit for clinical subprotocol  
• Removed pharmacokinetics assessment from clinical subprotocol  
• Added windows for visits  
 
 
COPPS   V9 | 20210921 
 
Confidential   Page 2 of 51 TITLE: COVID -19 Outpatient Pragmatic Platform Study (COPPS):  
A pragmatic multi -arm, adaptive, phase 2, blinded, randomized placebo -
controlled platform trial to assess the efficacy of different investigational 
therapeutics in reducing time to disease resol ution or viral load cessation, as 
compared to standard supportive care in outpatients with COVID -19 
 
ClinicalTrials.gov registration Number: [STUDY_ID_REMOVED]  
Study Document: Protocol (Version 9 , 21 September , 202 1)  
Study Phase: 2 
IND Number:   
Sponsor: Manisha Desai  
 
Version 9/ Version Date ( 21 September , 2021) 
 
        
CONTACT INFORMATION:  
 
Principal Investigator : 
Manisha Desai  Ph.D.  
Professor (Research) of Medicine (Biomedical Informatics)  
Professor o f Biomedical Data Science  
1701 Page Mill Rd  
Palo Alto,   California   94304 -1210  
Email: manishad@stanford.edu  
Phone:   
 
        

COPPS   V9 | 20210921 
 
Confidential   Page 3 of 51 PROTOCOL SIGNATURE PAGE  
 
 
Protocol Title: COVID -19 Outpatient Pragmatic Platform Study (COPPS):  
A pragmatic multi -arm, adaptive, phase 2, blinded, randomized placebo -
controlled platform trial to assess the efficacy of different investigational 
therapeutics in reducing time to disease resolution or viral load cessation, as compared to standard supportive care in outpatients with COVID -19 
 Protocol /IND  Number:  
 Pr 
otocol Version/Date:  Version 9 / 21 September   2021 
 
Sponsor Name:  Manisha Desai  Ph.D.  
Professor (Research) of Medicine (Biomedical Informatics)  
Professor o f Biomedical Data Science  
1701 Page Mill  Rd  
Palo Alto,   California   94304 -1210  
Email: manishad@stanford.edu  
Phone:   
 
Declaration of Investigator 
I confirm that I have read the above -mentioned protocol and its attachments. I agree  to conduct 
the described trial in compliance with all stipulations of the protocol, regulations and ICH E6 
Guideline for Good Clinical Practice (GCP).  
 
Principal Investigator Name:  __________________________________________  Principal Investigator Signature:  _______________________________________ 
 Date:   ___________________ 
Date (MM/DD/YYYY)  
 
Statement of Compliance  
The signature below provides the necessary assurance that this study will be conducted according to all stipulations of the protocol including statements regarding confidentiality, and according to local legal and regulatory requirements, US federal regulations, and ICH E6(R2) GCP guidelines.  Site Investigator Name:   __________________________________________ 
 Site Investigator Signature:  _______________________________________ 
 Date:   ___________________ 
Date (MM/DD/YYYY)  

COPPS   V9 | 20210921 
 
Confidential   Page 4 of 51 TABLE OF CONTENTS  
 
 
Protocol Team Roster  ................................................................................................................................ 7  
PROTOCOL SYNOPSIS  ........................................................................................................................... 8  
1. OBJECTIVES ................................................................................................................................ 16 
1.1. Primary Objecti ve ................................................................................................................ 16 
1.2. Secondary Objectives  ........................................................................................................ 16 
1.3   Exploratory Objectives  ..................................................................................................... 17 
2. BACKGROUND ............................................................................................................................ 17 
2.1 Study Disease...................................................................................................................... 17 
2.2 Treatment Rationale and Investigational Agent Information ........................................ 17 
2.3 Study Design ........................................................................................................................ 18 
2.3.1 Selection of Study Sites  ......................................................................................................... 18 
2.3.2 Subject Information and Consent  ......................................................................................... 19 
3. PARTICIPANT SELECTION AND ENROLLMENT PROCEDURES  .................................... 20 
3.1 Inclusion Criteria .................................................................................................................. 20 
3.2  Exclu sion Criteria  ............................................................................................................... 20 
3.3  Randomization Procedures  .............................................................................................. 22 
3.4  Common Control Arm  ........................................................................................................ 22 
3.4.1 Maintaining the Blind in the Presence of Drugs Administered Heterogeneously  .......... 22 
3.4.2 Benefits and trade- offs to the common control group  ....................................................... 22 
3.5    Prohibited Concomitant Therapy for Viral Domain  ........................................................ 23 
3.6    Prohibited Concomitant Therapy for Clinical Domain.................................................... 23 
4.      STUDY PROCEDURES  .............................................................................................................. 24 
4.1 Schedule of Assessments  ............................................................................................................ 24 
4.2 Study Procedures  .......................................................................................................................... 26 
4.3  Clinical Lab Biomarkers  .................................................................................................... 27 
5. MEASUREMENTS ....................................................................................................................... 28 
5.1  Primary and Secondary Outcome measures  .................................................................. 28 
5.1.1 Relevant Subset   ............................................................................................................... 28 
5.1.2 Measurement Definition ......................................................................................................... 28 
5.1.3 Measurement Methods  .......................................................................................................... 29 
5.2 Secondary Outcomes  ......................................................................................................... 31 
6. STATIST ICAL CONSIDERATIONS  ........................................................................................... 32 
6.1 Statistical Design  ................................................................................................................. 32 
6.1.1  Randomization  ................................................................................................... 32 
6.2 Descriptive Statistics and Exploratory Data Analysis  .................................................... 33 
6.3 Primary Analysis .................................................................................................................. 33 
6.3.1  Analysis Population........................................................................................... 33 
6.3.2  Analysis Plan  ..................................................................................................... 33 
6.4 Secondary Analysis  ............................................................................................................ 34 
COPPS   V9 | 20210921 
 
Confidential   Page 5 of 51 6.4.1  Analysis Population........................................................................................... 34 
6.4.2 Analysis Plan   ............................................................................................................... 34 
6.5  Interim analyses  ................................................................................................................. 34 
6.6 Missing Data Handling .................................................................................................................. 34 
6.6.1 Missing Data Methods – Viral Domain  ................................................................................. 35 
6.6.2 Missing Data Methods – Clinical Domain  ............................................................................ 35 
6.6.3 Missing Data Methods – Censoring ..................................................................................... 36 
6.7  Sample Size Justification  ................................................................................................... 36 
6.8 Criteria for stopping enrollment into a treatment  ............................................................ 37 
7. DATA AND BIOSPECIMEN COLLECTION, RETENTION AND MONITORING  ....................... 37 
7.1 Data collection instruments  .......................................................................................................... 37 
7.2 Data management procedures  .................................................................................................... 38 
7.3 Data quality control and reporting ............................................................................................... 38 
7.4 Archival of data  ............................................................................................................................... 38 
7.5 Availability and retention of investigational records  .................................................................. 38 
7.6 Subject confidentiality  .................................................................................................................... 38 
7.7 Audit   ............................................................................................................................................... 39 
8 ADVERSE EVENT REPORTING AND DOCUMENTATION  ................................................. 39 
8.1 Adverse Events  .............................................................................................................................. 39 
8.2 Definition  of an Adverse Event  ..................................................................................................... 40 
8.2.1 Evaluating and Reporting of Adverse Events  ..................................................................... 40 
8.3 Serious Adverse Events (SAEs)  .................................................................................................. 42 
8.3.1 Definition of Serious Adverse Events ................................................................................... 42 
8.3.2 SAE Reporting Requirements to the Sponsor  .................................................................... 43 
8.4 Suspected Unexpected Serious Adverse Reactions (SUSARs)  ............................................ 43 
8.4.1 Reporting SUSARs to the FDA: IND Safety Reports  ........................................................ 44 
8.5 Clinical Laboratory Abnormalities and Other Abnormal Assessments  .................................. 44 
8.6 Handling of Overdose .................................................................................................................... 44 
8.7 Management of Progression of Disease  .................................................................................... 44 
9 WITHDRAWAL OF SUBJECTS AND MANAGEMENT OF PROTOCOL VIOLATIONS  ........... 46 
9.1 Withdrawal of subjects from the study  ........................................................................................ 46 
9.2 Removal of subjects from the study  ............................................................................................ 46 
9.3 Protocol Violations  ......................................................................................................................... 46 
10 DATA, SAFETY, & MONITORING  ................................................................................................... 46 
10.1 Data and Safety Monitoring Board (DSMB)  ............................................................................. 47 
11. GOVERNANCE  ................................................................................................................................. 49 
12. ADMINISTRATIVE , ETHICAL, REGULATORY CONSIDERATIONS  ....................................... 50 
12.1 Institutional review board  ............................................................................................................ 50 
12.2 Informed consent form  ................................................................................................................ 50 
12.3 Discontinuation of the Study  ...................................................................................................... 50 
12.4 Use of Information and Publication ........................................................................................... 51 
APPENDIX 1: SUB- PROTOCOLS  ........................................................................................................ 51 
COPPS   V9 | 20210921 
 
Confidential   Page 6 of 51  
COPPS   V9 | 20210921 
 
Confidential   Page 7 of 51 Protocol Team Roster  
Investigators for COPPS                                        
  
Manisha Desai, PhD, Professor of Medicine and of Biomedical Data Science, 
Quantitative Sciences Unit, Stanford University  
Address: 1701 Page Mill Road, Palo Alto, CA 94304  
Email: manishad@stanford.edu  
 
Upinder Singh, MD, Professor, Division of Infectious Diseases and Geographic 
Medicine, Department of Medicine, Stanford University  
Address: Lane Building, , 300 Pasteur Dr, Stanford, CA 94305  
Email: usingh@stanford.edu  
 
Yvonne Maldonado, MD, Professor, Division of Infectious Diseases, Department of 
Pediatrics, Stanford University  
 A ddress: 730 Welch Road, , Palo Alto, CA 94304  
 Email: bonnim@stanford.edu  
 
Chaitan Khosla, PhD, Professor, Department of Chemical Engineering, Stanford 
University  
 Address: 290 Jane Stanford Way, , Stanford, CA, 94305  
 Email: khos la@stanford.edu 
 
Haley Hedlin, PhD, Associate Director of Clinical Trials, Quantitative Sciences Unit, Stanford University  
Address: 1701 Page Mill Road,  Palo Alto, CA 94304  
Email: hedlin@stanford.edu  
 
Investigators for COPPS  Sub- Protocols  
Investigators for  COPPS Sub- Protocol for Acebilustat  
Angela Rogers, MD, Assistant Professor, Division of Pulmonary, Allergy & Critical Care Medicine, Department of Medicine, Stanford University  
 Address: 300 Pasteur Dr. , Stanford CA 94305  
 Email: ajrogers@stanford.ed u 
 Joseph Levitt, MD, Assistant Professor, Division of Pulmonary Medicine, Department of Medicine, Stanford University  
 Address:  , Stanford, CA 94305  
 Email: jlevitt@stanford.edu  
 
Investigator for COPPS  Sub- Protocol for Camostat  Mesilate  
Julie Parsonnet, MD, Professor, Stanford University, Division of Infectious Diseases and Geographic Medicine, Department of Medicine 

COPPS   V9 | 20210921 
 
Confidential   Page 8 of 51  Address: Lane Building Room , Stanford, CA 94305- 5107  
Email: parsonnt@stanford.edu  
 
 
Multi -Site Coordinator:  
, MPH, MSED, Study Startup Operations Associate, Stanford 
University  
Email: @stanford.edu  
 
PROTOCOL SYNOPSIS  
TITLE  COVID -19 Outpatient Pragmatic Platform Study 
(COPPS):  
A multi -arm, adaptive, phase 2, blinded, randomized 
placebo- controlled platform trial to assess the efficacy of 
different investigational therapeutics in reducing time to 
disease resolution or viral load cessation, as compared to 
standard supportive care in outpatients with COVID -19 
STUDY PHASE  2 
DESIGN  The platform trial allows arms to have one of two primary 
objectives: one evaluating viral shedding (A. Viral Domain); and another evaluating clinical  outcomes (B. Clinical 
Domain).  The investigational product of interest  and its 
mechanism of action and scientific rationale will dictate which objective is primary under its sub- protocol (i.e., either 
A. Viral Domain or B. Clinical Domain). The other Dom ain 
objective will be a secondary measure for the investigational product  of interest. The platform trial will 
also include a common control arm that will be used as a comparator for all arms in both Domains. Investigational products will not be compared t o each other.  
 The primary purpose of the Viral Domain endpoint is to examine the basic mechanisms of action on the viral shedding and viral load for the investigational therapies in this Domain.  The primary purpose of the Clinical Domain is to evaluate if one or more of the investigational therapies in this Domain is effective in treating the symptoms and clinical manifestation of COVID -19.   
 
This is an adaptive study, wherein investigational therapies can be dropped or added during the trial.  Patients will be randomized to one of the investigational therapies in either the Viral or Clinical Domain, or to the control group.  Currently, there is one interventional product in the Viral 
Domain and one interventional product in the Clinical 

COPPS   V9 | 20210921 
 
Confidential   Page 9 of 51 Domain. All sub -protocols will be double -blinded  at the drug 
level. Investigators and participants will know to which sub-
protocol the participants  are assigned ; they will not know if 
they are receiving drug or placebo. The study is a 
multicenter trial that will be conducted in up to 5 sites 
nationwide.  
INDICATION  Outpatients with confirmed positive symptomatic mild -to-
moderate COVID -19 
INVESTIGATIONAL 
PRODUCT(S) OR 
PROCEDURE(S)  A. Viral Domain  
1. Camostat, administered as 200 mg, four times a day for 
ten days  
B. Clinical Domain  
1.  Acebilustat administered as a 100- mg capsule once 
daily for 28 days  
Common Control  
Placebo tablets; the appearance (and dosing scheme) will 
be randomized out of available therapies.  
PRIMARY 
OBJECTIVE(S)  The platform study has two key domains evaluating either (A) viral shedding or (B) clinical events. Each investigational product will belong in only one domain.  
The primary objective for each respective domain is as follows, tailored to the mechanism of action and scientific rationale of the drugs being considered in each domain.  
A. (Viral Domain) To evaluate the efficacy of each therapeutic intervention in addition to standard supportive care compared with standard supportive care in reducing viral shedding of SARS -CoV-2 virus in 
outpatients with  COVID -19 disease.  
B. (Clinical Domain) To evaluate the efficacy of each 
therapeutic intervention in addition to standard 
supp ortive care as compared to standard supportive 
care in improving sustained clinical outcomes in 
outpatients with COVID -19 disease.  
SECONDARY 
OBJECTIVES  Secondary objectives are:  
1. To address the primary objective for the non-
membership domain of the investigational product (see above).  
a. For example, if Drug X falls under the Viral Domain, a secondary objective will be the primary objective listed under the Clinical 
Domain.  
2. To evaluate the efficacy of each therapeutic intervention 
in reducing SARS -CoV-2 related hospitalizations, ED 
COPPS   V9 | 20210921 
 
Confidential   Page 10 of 51 visits, or death in outpatients with COVID -19 disease.  
3. To assess the development of antibodies against  SARS-
CoV-2  
4. To evaluate the safety and tolerability of each 
therapeutic intervention compared with placebo (supportive care).  
INCLUSION 
CRITERIA  Inclusion Criteria can be tailored to each investigational 
product. However, some inclusion criteria are shared among all arms in the platform in both domains  
1. Adults (18- 80 years inclusive)  
2. Outpatient  
3. Symptomatic  
4. FDA-cleared molecular diagnostic assay positive for 
SARS- CoV-2 within 72 hours from initial swab to the 
time of commencing informed consent  
5. Subject’s COVID- 19 related symptom  onset occurred 
within  7 days prior to time of randomization.  
6. Willing and able to comply with responsibilities necessary for trial integrity.  
7. Other inclusion criteria specific to the investigational product that may, in the eyes of the investigator, be deemed necessary.  
EXCLUSION 
CRITERIA  Exclusion Criteria is tailored to each investigational product. However, some exclusion criteria are shared among all arms in the platform in both domains  
1. At screening, the subject needs  to be admitted to the 
hospital or is being evaluated for potential admission  
2. Previous use of experimental drugs that may be 
active against COVID -19 in the eyes of the 
investigators.  
3. At screening, subject  tests positive by  a urine  
pregnancy test.  
4. Subject is using adrenocorticosteroids (except topical 
or inhaled preparations or oral preparations equivalent to or less than 10 mg of oral prednisone) or immunosuppressive or immunomodulatory drugs (e.g., immunosuppressants, anticancer drugs, interleukins, interleukin antagonists or interleukin receptor blockers).  
NOTE: Treatment of study participants 
following institutional COVID -19 treatment 
policies or guidelines, including the use of 
COPPS   V9 | 20210921 
 
Confidential   Page 11 of 51 immunomodulatory medications, is permitted. 
This excludes treatment with agents that have 
the potential for direct antiviral activity, including convalescent plasma and NO, and co-enrollment into other clinical studies that 
evaluate investigational agents for COVID -19. 
 
5. Subject has a serious chronic disease (e.g., uncontrolled hum an immunodeficiency virus [HIV], 
cancer requiring chemotherapy within the preceding 6 months, and/or moderate or severe hepatic insufficiency).  
6. Has renal insufficiency including severe renal impairment and ESRD and/or  requiring hemodialysis 
or continuous ambulatory peritoneal dialysis (CAPD).  
7. Has liver impairment greater than Child Pugh A.  
8. Has a history of alcohol or drug abuse in the previous 
6 months.  
9. Has a psychiatric disease that is not well controlled where controlled is defined as: stable on a regimen for more than one year.  
10. Has taken another investigational drug within the past 30 days.  
11. Is deemed by the Investigator to be ineligible for any reason.  
OUTCOME 
MEASURES  The primary outcome is determined by its Domain.  
The primary outcome in the non- assigned Domain is a 
required secondary outcome.  
Viral Domain Primary Outcome (Clinical Domain Secondary 
Outcome):  
● Change in viral  shedding of SARS -CoV-2 virus  
through day 10 from self -collected nasal swabs . 
Clinical Domain Primary Outcome (Viral Domain 
Secondary Outcome):  
● Time from randomization to sustained symptom 
resolution . Resolution is defined as the first  day 
where no symptoms are self -reported on all 
succeeding days through and including day 28,  not 
including sense of taste or smell, and defining 
recovery for fatigue and cough as mild or none. 
Note: A feature of the pragmatic platform design is that 
COPPS   V9 | 20210921 
 
Confidential   Page 12 of 51 new investigational products may choose a different 
primary endpoint given the available data collected 
under the platform (see below).  
Study  
Measurements: 
Efficacy, Safety  
     Study measurements are largely shared between both 
domains with a pragmatic, shared infra structure   
While the infra structure  is shared, each investigational 
product may have necessary details tailored to the product of study to meet the needs for research and participant safety.
 
Shared in both Domains:  
● Daily self -assessed symptomology surveys (days 1-
28) 
● In-person clinic assessments on days 1, 5, and 28  
● Laboratory panels at screening and at each in person visit to ensure safety (Liver & Renal function, urinalysis)  
● Self-administered nasal swabs on days 1-
10,14,21,28 for SARS -COV -2 viral quantification  
● Telehealth call on day s 120, 210, 300 
Viral  Domain Specific:  
● In-person clinic assessments on day  10  
Clinical  Domain Specific:  
● Day 10 and 35 telehealth visit s 
SAMPLE SIZE  60 participants for each arm including the shared control 
arm. Total participants will change dynamically  based on 
the number of investigational products in the platform.  
STATISTICAL 
CONSIDERATIONS  We will evaluate the intention -to-treat (ITT) population, 
defined according to the assigned randomization arms, for the primary efficacy analysis. We will analyze the as -
treated population as supportive evidence for the primary efficacy analysis. We conservatively assume that 90% of participants will complete follow -up. The primary endpoint 
will be assessed in all patients within their respective domain.  
 With 60 patients randomized per arm, we will have 80% power to detect an effect size of 0.5  in virologic shedding in 
participants receiving one of the investigational therapies 
from the Viral Domain.  
 
With 60 patients randomized per arm, we will have 80% 
power to detect a hazard ratio of 1.91  (assuming a median time to event of 10 days in the control arm) in time to symptom resolution, assuming a 5% loss to follow up in 
each arm and 5% significance level (two -sided).   
COPPS   V9 | 20210921 
 
Confidential   Page 13 of 51  
  Figure 1.  Schema for study inclusion; A1, A2, B1 represent different theoretical 
investigational products   
 
   
Figure 2.  Enrollment  timeline; A1, A2, A3, B1 represent different  theoretical  
investigational products .  

COPPS   V9 | 20210921 
 
Confidential   Page 14 of 51  

COPPS   V9 | 20210921 
 
Confidential   Page 15 of 51 LIST OF ABBREVIATIONS AND DEFINITION OF TERMS  
 
AE Adverse event  
BID Twice daily  
CBC  Complete blood count  
CI Confidence interval  
CRF Case report/Record form  
DAIDS  Division of AIDS  
DSMB  Data Safety Monitoring Board  
EUA Emergency Use Authorization  
GI Gastrointestinal  
Hgb Hemoglobin  
HIV Human Immunodeficiency Virus  
IRB Institutional Review Board  
MAb Monoclonal antibody  
Platform Trial  A clinical trial to evaluate several interventions simultaneously  
PLT Platelet  
QD Once daily  
SAE Serious adverse event  
Sub-Protocol  Aspects of the protocol that are specific to an intervention  
Domain  A study of interventions evaluated by a shared primary 
endpoint  
WBC  White blood cell  
WHO  World Health Organization  
 
  
COPPS   V9 | 20210921 
 
Confidential   Page 16 of 51 1. OBJECTIVES  
While global efforts to identify effective therapeutics to treat COVID -19 are intensifying 
and limited anecdotal data suggests that some drugs may be effective, particularly in 
the inpatient setting, we currently lack robust data that  demonstrate the effic acy of 
widely available therapeutic agents for  outpatients with COVID -19. There remains an 
urgent public health need to develop novel interventions. The overall objective of this study is to efficiently evaluate the clinical efficacy and safety of different investigational therapeutics among adults who have COVID -19 but are not yet sick enough to require 
hospitalization. Our overall hypothesis is that through an adaptive trial design, we will be able to identify potential effective therapies (single and combination) for this  group of 
patients.  
 COVID -19 Outpatient Pragmatic Platform Study (COPPS) is a pragmatic platform 
protocol designed to evaluate COVID -19 treatments by assessing their ability to reduce 
viral shedding (Viral Domain) or improve clinical outcomes (Clinical Domain). To be included into the platform, every investigational product will collect data for both Domain primary endpoints. Individual treatments to be evaluated in the platform will be described in separate sub- protocols.  
 1.1. Primary Objective   
The platform study allows investigational products with objectives either: evaluating viral shedding (Virology Domain); and COVID -19 related Clinical Outcomes (Clinical 
Domain).  
The primary objective for investigational products within the Viral Domain is :  
A. To evaluate the efficacy of each therapeutic intervention in addition to standard supportive care (SSC)  compared with SSC  in reducing viral shedding of SARS -
CoV-2 virus in outpatients with COVID -19 disease. 
The primary objective for investigational products within for the Clinical Domain is:  
B. To evaluate the efficacy of each therapeutic intervention in addition to SSC as 
compared to SSC in improving sustained clinical outcomes in outpatients with 
COVID -19 disease.  
 1.2. Secondary Objectives  
Secondary obj ectives are:  
1) The objective of the non- assigned domain an investigational product is under.  
a. If under Clinical Domain, reduction in viral shedding.  
b. If under Viral Domain, time to sustained resolution of symptoms.  
2) To evaluate the efficacy of each therapeutic intervention in reducing SARS -CoV-
2 related hospitalizations, ED visits, or death in outpatients with COVID -19 
disease.  
3) To assess the development of antibodies against SARS -CoV-2  
COPPS   V9 | 20210921 
 
Confidential   Page 17 of 51 4) To evaluate the safety and tolerability of each therapeutic intervention compared 
with placebo (supportive care).  
1.3   Exploratory Objectives  
Exploratory objectives are specific to each sub- protocol and will be specified in their 
respective appendices.  
 
2. BACKGROUND  
 
2.1 Study Disease  
The COVID -19 pandemic is an unpr ecedented global health crisis. COVID -19 is a 
respiratory disease caused by a novel coronavirus (SARS -CoV-2). The virus is highly 
transmissible and causes life- threatening acute respiratory symptoms in a high 
percentage of cases, especially amongst the elderly and in patients with underlying conditions. Globally, there are currently over 120 million cases of COVID- 19 and more 
than 2.79 million  fatalities. In the United States alone, there have been over 5 00,000  
deaths. These numbers continue to grow each day, with projections of hundreds of thousands of deaths in the United States alone before the pandemic is fully controlled.  
 Given the enormous and rapidly escalating scale of the pandemic, there is an urgent public health need to identify effective therap eutics for treating COVID -19. We propose 
to conduct a clinical trial to evaluate several investigational therapeutics for the treatment of adults with COVID -19. The multi -site trial (anticipating up to 5 additional 
sites) is based at Stanford University . We will evaluate a suite of potential therapeutics 
including antivirals and immunomodulatory agents. Together, we are situated to conduct this trial, with world renowned experts in immunology, infectious diseases, biostatistics and a sophisticated infrastructure for efficiently conducting clinical trials. The unprecedented nature of the COVID -19 pandemic requires a collaborative approach to 
address this public health crisis. In addition, collecting clinical and virologic data on enrolled subjects should provide valuable information about the clinical course of and morbidities associated with COVID -19 in a diverse group of patients. At the conclusion 
of this clinical trial we expect to have identified potentially effective therapeutic strategy/ies for treating  COVID -19, which will have a transformative impact on precision 
medicine and public health.   
2.2 Treatment Rationale and Investigational Agent Information 
For drugs considered under  the Viral Domain, we look for candidates with potential 
activity to  influence viral mechanism of activity , including those that block viral entry in 
vitro, viral replication and/or viral trafficking.  
 
For drugs considered for the Clinical Domain, we look for candidates with potential ability to improve clinical outcomes.  
 See individual treatment sub- protocols in Appendix 1  for robust rationale.  
 
COPPS   V9 | 20210921 
 
Confidential   Page 18 of 51 2.3 Study Design 
This platform  study is designed to primarily evaluate efficacy  compared to standard of 
care (SOC) in addition to placebo . The platform trial allows arms to have one of two 
primary objectives: one evaluating viral shedding (A. Viral Domain); and another 
evaluating clinical outcomes (B. Clinical Domain).  The investigational product of interest, likely anti -viral or anti -inflammatory in nature, and its mechanism of action and 
scientific rationale will dictate which objective is primary under its sub- protocol (i.e., 
either A. Viral Domain or B. Clinical Domain). The other Domain objective will be a secondary measure for the investigational drug of interest. The platfo rm trial will also 
include a common control arm that will be used as a comparator for all arms in both Domains. Investigational products will not be compared to each other.  
 
The primary purpose of the Viral Domain endpoint is to examine the basic mechanism s 
of action on the viral shedding and viral load for the investigational therapies in this 
Domain.  The primary purpose of the Clinical Domain is to evaluate if one or more of the investigational therapies in this Domain is effective in treating the symptoms and clinical manifestation of COVID -19.   
 
This is an adaptive study, wherein investigational therapies can be dropped or added 
during the trial.  Patients will be randomized to one of the investigational therapies in either the Viral or Clinical Domain, or to the control group.  Currently, there is one interventional product in the Viral Domain and one interventional product in the Clinical Domain. All sub -protocols will be double- blinded  at the drug level . Investigators and 
participants will know to wh ich sub -protocol a participant is  assigned; they will not know 
if they are receiving drug or placebo. 
 SOC at Stanford is defined as methods Stanford University Healthcare is using for 
COVID -19 patients at the time of study initiation. Each site’s local SO C to be defined 
and shared with Sponsor prior to study initiation.  
 2.3.1 Selection of Study Sites  
 This study is being supported by the Stanford Innovative Medicines Accelerator (IMA), Clinical Trials Research Unit (CTRU), and the Stanford Center for Clinical Research. The study will be performed at up to 5 sites nationally , to be determined by  the Clinical 
Coordinating Center  at Stanford. 
 The local sites will be responsible for screening patients and evaluating the appropriateness of therapy administration for each participant at study enrollment in addition to the conduct of the trial protocol. The local site investigators will also be fully responsible for ensuring timely data collection, adverse event monitoring, maintenance of regulatory c ompliance.  Compensation, if any, may be determined locally and in 
accordance with local IRB requirements and approval.   
 
COPPS   V9 | 20210921 
 
Confidential   Page 19 of 51 Each investigator or group of investigators at a clinical site must obtain Institutional Review 
Board (IRB) approval for this protocol and submit all required regulatory documents (including any protocol specific documents) to their respective IRB as required per institution. Sites can submit through a Stanford- designated central IRB for this trial. All 
subsequent mentions of IRB related activity in this document will reflect whichever choice they decide, be it local or central IRB.  
Requirements for site selection and site registration:  Sites will be evaluated by 
Stanford team and the main PI prior to selection or activation.  
Stanford requires documentation that verifies IRB -approval for this protocol, informed  
consent documents, and associated documents prior to recruitment, screening, and enrollment  
of subjects, and any IRB -approvals for continuing review or amendments.  
 Please refer to the MOP for information on:  
• Requesting and submitting regulatory documents  
• Patient enrollment & randomization 
• Randomization notification 
• Requesting study drug 
• Withdrawals  
• Lost to follow -up 
• Protocol deviations  
• Data submissions  
 2.3.2 Subject Information and Consent  
It is the responsibility of the Site Investigator to ensure that written informed consent is obtained from the subject or legal representative before any activity or procedure is undertaken that is not part of routine care. The informed consent must comply with local regulations.  
The background of the study, the procedures, the potential benefits and risks of the treatment, and the fact that treatment is voluntary for the subject must be explained to the subject or legal representative. The subject or representative must be given s ufficient time 
to consider whether to receive other  treatment  options . A copy of the ICF, signed and 
dated by the subject/representative and the Site Investigator (or designee), must be given to the subject/representative. Confirmation of a subject’s infor med consent must also be 
documented in the subject’s medical record prior to any treatment.  
Each consent form should contain an authorization allowing the Investigator and the Sponsor (or designee) to use and disclose protected health information (PHI) (i.e., subject -
identifiable health information) in compliance with local law. The signed consent form will be retained with the treatment records.  
 
COPPS   V9 | 20210921 
 
Confidential   Page 20 of 51 3. PARTICIPANT SELECTION AND ENROLLMENT PROCEDURES  
Participants of this trial are meant to be those with diagnosed COVID -19 with severity 
ranging from mild  through moderate disease without contraindications for a given 
investigational product.  
3.1 Inclusion Criteria  
 
1. Outpatient setting  
2. Age ≥ 18 years and ≤ 80 years at the time of the assessment  
3. Able and willing to understand the study, adhere to all study procedures, and provide 
written informed consent   
4. Initial diagnosis of COVID- 19 disease as defined by an FDA -cleared molecular 
diagnostic assay  positive for SARS -CoV-2 with no more than  72 hours from the 
initial swab used in the diagnosis to the time of commencing informed consent.   
5. At baseline, at least two symptoms should have mild or higher severity score, where 
at least one of the mild symptoms is not cough, fatigue, or loss of smell/taste OR at 
least one symptom has a  moderate or higher severity score on the COVID 
Outpatient Symptom Scale (COSS) . 
6. Subject’s COVID- 19 related symptom  onset occurred within 7 days prior to time of 
randomization . 
7. Additional inclusion criteria may pertain to specific drugs and will be described in Appendix 1 
 
3.2  Exclusion Criteria  
 
1. At screening, the subject needs to be admitted to the hospital or is being evaluated for potential admission.  
2. Previous use of experimental drugs that may be active against C OVID -19 in the 
eyes of the investigators   
3. Participant yields a positive urine pregnancy test at screening.  
4. Subject is using adrenocorticosteroids (except topical or inhaled preparations or oral preparations equivalent  to or less than 10 mg of oral prednisone) or 
immunosuppressive or immunomodulatory drugs (e.g., immunosuppressants, anticancer drugs, interleukins, interleukin antagonists or interleukin receptor blockers). 
NOTE: Treatment of study participants following institutional COVID- 19 treatment 
policies or guidelines, including the use of immunomodulatory medications, is permitted. This excludes treatment with agents that have the potential for direct antiviral activity, including convalescent plasma and NO, and c o-enrollment into 
other clinical studies that evaluate investigational agents for COVID -19.  
COPPS   V9 | 20210921 
 
Confidential   Page 21 of 51 5. Subject has a serious chronic disease (e.g., uncontrolled human immunodeficiency 
virus [HIV], cancer requiring chemotherapy within the preceding 6 months, and/or moderate or severe hepatic insufficiency).  
6. Has renal insufficiency including severe renal impairment and ESRD and/or requiring hemodialysis or continuous ambulatory peritoneal dialysis (CAPD).  
7. Has liver impairment greater than Child Pugh A.  
8. Has a history of  alcohol or drug abuse in the previous 6 months.  
9. Has a psychiatric disease that is not well controlled where controlled is defined as: stable on a regimen for more than one year.  
10. Has taken another investigational drug within the past 30 days.  
11. Is deemed by the Investigator to be ineligible for any reason.  
12. Additional exclusions may pertain to specific drugs’ sub protocol  listed under  
Appendix 1 
 
NOTE:  
Additional Criteria for Monoclonal Antibody (MAb) Therapy Under Emergency Use 
Authorization (EUA) : 
 Patients who are considered high- risk based on criteria for receiving monoclonal 
antibody therapy under EUA by FDA must be informed of its availability and offered 
referral to receive MAb as background standard supportive care. These high -risk 
patients  are identified as  those with the following conditions :  
• Older age (aged ≥65 years)  
• Obesity (BMI >30)  
• Diabetes  
• Cardiovascular disease (including congenital heart disease) or hypertension  
• Chronic lung diseases (e.g., chronic obstructive pulmonary disease, moderate -to-
severe asthma, interstitial lung disease, cystic fibrosis, pulmonary hypertension)  
• An immunocompromising condition or immunosuppressive treatment  
Note: These criteria may be revised based on any future updates to the “FDA panel 
recommendations Food and Drug Administration Emergency Use Authorization Criteria 
for Use of Anti -SARS- CoV-2 Monoclonal Antibodies ”. 
Patients will be referred to receive MAb therapy based on the study site/inst itution’s 
referral process.  The site will document whether referral for MAb therapy was offered 
and whether the patient accepted or refused such therapy. This information will be 
entered in RedCapCloud Electronic Data Capture system  as part of the case report 
form.  
 
COPPS   V9 | 20210921 
 
Confidential   Page 22 of 51 3.3  Randomization Procedures  
Patients will be randomized to one of the investigational therapies or the common 
control arm (See Figure 1 ).  A biased coin randomization using age (>=50 years of 
age), sex , receipt of baseline monoclonal antibodies, and site  as inputs will be used to 
balance each arm. Patients randomized to the placebo arm will be further randomized to a sub- protocol that will determine the type of placebo treatment the patient receives 
and study procedures for any minor processes that may differ across sub- protocols to 
maintain blinding.  Randomization will be performed from a centralized web- based 
system that all sites will have access to.  
 
3.4  Common Control Arm  
A subset of the common control arm will be used as the comparison for each indi vidual 
treatment. The subset will be determined by participant eligibility and time of enrollment. 
Patients in the common control arm will be included in the comparison group for any treatment that the patient could have been randomized to, regardless of which sub-protocol they were randomized to, similar to implementation of other Master Trials including the U.K. -based RECOVERY trial. At the time of randomization, we will record 
the treatments the patient could have been randomized to (based on eligibility  criteria 
and the treatments available under the pragmatic platform protocol at the time of randomization). This maintains comparability between the study arm of interest and the controls used as comparators with respect to secular time and eligibility cri teria.   
 Treatment arm  randomization odds  can and will change under COPPS  as drugs are 
introduced and graduated over time. Controls can only be shared for the purpose of 
answering a particular question about an investigational product  if the participant could 
have been randomized to that particular  investigational product and they were eligible 
for that particular investigational product at time of participant enrollment.  In a special 
case where a n ongoing trial is incorporated into COPPS , only newly randomized eligible 
controls may be shared.  
 3.4.1 Maintaining the Blind in the Presence of Drugs Administered Heterogeneously  
Patients in the common control arm will be randomized to receive a placebo treatment corresponding to one of the treatments currently available under the pragmatic platform protocol (selected at random). Each treatment will have matching placebo tablets to be taken on the same schedule as the active tablets. If a treatment is added to the pragmatic platform protocol that are not tablets (e.g. an injection), a placebo for that treatment will be available for all patients. Thus, as study arms are added, placebos that look like that study arm will also be added. The chosen placebo type will be randomly selected. Study investigators and patients will know to which sub- protocol a patient is 
assign ed to . Patients and investigators will be blinded to whether a patient receives an 
active or placebo version of the treatment .  
 3.4.2 Benefits and trade- offs to the common control group  
The benef its of the common control group involve improvements from both the 
perspective of the participant and investigator. From the participant point of view, the 
COPPS   V9 | 20210921 
 
Confidential   Page 23 of 51 pragmatic platform trial reduces the number  of participants needed to complete the trial, 
thus it puts fewer patients at risk . From an investigator’s point of view, there is efficiency 
gained from sharing controls  and coordinating recruitment and screening rather than 
competing for participants . 
 
However, the common control group has tradeoffs  in logistics for sharing control 
participants. Since a control participant may be utilized  in the analyses for more than 
one sub- protocol, data used for a key endpoint from any arm must be collected for all 
individuals in the platform. While each investigational arm  may have nuances tailored to 
the specific drug, the data collected must remain consistent across all arms, or the shared controls will have missing data when included in the analysis of a sub- protocol 
other than the one they were randomized to.  
 Another logistical consideration is the slight differences in inclusion criteria resulting 
from clinical considerations of each investigational product under consideration . An 
individual randomized to the common control group may be eligible for a single sub-protocol or sub- protocols for every investigational product currently available.  
3.5    Prohibited Concomitant Therapy for Viral Domain 
Any other antiviral medication whether investigational or approved.  
3.6    Prohibited Concomitant Therapy for Clinical Domain 
Any other immunomodulatory treatment whether investigational or approved  
 
  
COPPS   V9 | 20210921 
 
Confidential   Page 24 of 51 4.      STUDY PROCEDURES  
4.1 Schedule of Assessments  
 
 Table 1.  Domain Assessments (X is all domains, A is Acebilustat sub -protocol only, C is Camostat sub -protocol only, I is 
Acebilustat imaging sub -study only)  
Day of study  1 2 3 4 5 
±1 6 7 8 9 10 
±1 14 21 28 
+7 35
+7 90 
±7 120
±7 210 
±7 300 
±7 
Assessments in the clinic  X       X         C     X      
Physical exam  X       X         C   X      
Vitals  X       X         C   X      
Clinical status  X       X         C   X      
SpO2  X       X         C   X      
Urine Pregnancy Test  X            I3  I3    
Self-collected nasal swab  X X X X X X X X X X X X X      
COSS self -assessment  Every day from days 1 -28 inclusive  A  X X X 
Oropharyngeal swab  X       X         C   X      
Blood collected by phlebotomy for 
clinical labs  X       X         C   X      
 
 
COPPS   V9 | 20210921 
 
Confidential   Page 25 of 51  
 
 Table 1.  Domain Assessments (X is all domains, A is Acebilustat sub -protocol only, C is Camostat sub -protocol only, I is Acebilustat 
imaging sub -study only)  
Day of study  1 2 3 4 5 
±1 6 7 8 9 10
±1 14 21 28
+7 35
+7 90
±7 120
±7 210
±7 300
±7 
Blood collected by phlebotomy for 
biobanking  X1                     X1      
Blood collected by phlebotomy for PK         C1                     
Telehealth visit           A    A  X X X2 
CT Imaging  I3            I3  I3    
Administration of drug - Camostat sub -
protocol  C C C C C C C C C C         
Administration of drug - Acebilustat sub -
protocol  Every day from days 1 -28 inclusive       
1-Denotes optional assessment.  
2-Denotes additional telehealth visit if needed for following any ongoing AEs.  
3-Imaging visit window: the baseline scan should occur up to and including Day 3 while on trial. D28 and D90 have a window of ± 3 Days. 
Women of childbearing potential are required to complete a pregnancy test prior to their Baseline, Day 28, and Day 90 scans. 
COPPS   V9 | 20210921 
 
Confidential   Page 26 of 51 4.2 Study Procedures  
Day 1 (PRE -DOSE)  
• Obtain informed consent . 
• Verify eligibility per the inclusion and exclusion criteria.  
o Review and record medical history to ensure there are no exclusionary illnesses.  
o Review and record concomitant medications for possible prohibited medications.  
o Record date of onset of symptoms  
• If subject is female of child- bearing potential and meets inclusion criteria obtain urine 
pregnancy test and proceed if result is negative.  
• Measure and record vital signs ( BP, HR, Temp, Resp, SPO2).  
• Perform Physical exam (may be done by the Principal Investigator or their designee)  
• Collect oropharyngeal swab for virologic testing.   
• Collect blood samples for:  
o Antibodies to SARS -CoV-2. 
o Hematology and clinical chemistry laboratory analyses  
o Biobanking, if applicable 
• Randomize to available treatments . 
• Explain in home procedures for the study (self -sampling of nasal swabs, temperature, 
SPO2, completing the daily questionnaire).  
• Provide supplies to research subject and review  the calendar of return visits  
 
Day 1 (FIRST DOSE AND POST -DOSE)  
NOTE: Day 1 is deemed to be the first 24 hours after enrollment into the study, with time 
0 (time of first dose) occurring as quickly as possible after the subject’s eligibility has been confirmed.  
• Administer first dose at time 0.  
o Subjects randomized to the camostat mesi late arm  will receive 200mg of active 
camostat mesylate or matching placebo one hour before meals (breakfast, lunch, 
and dinner) and before bedtime, for 800mg total in a day over 4 dosing periods. Camostat mesilate is provided as 100 mg tablets and dosed orally. Subjects will be instructed to take their doses at least two hours after a meal and one hour before the next meal, and at bedtime  
o Subjects randomized to the acebilustat arm  will rece ive a 100-mg capsule of 
active acebilustat or matching placebo capsule administered orally once daily for 28 days.  
• Monitor participant  for at least 15 minutes after their first dose.  
COPPS   V9 | 20210921 
 
Confidential   Page 27 of 51 • Educate participant  on the dosing schedule  for the arm  to which they are assigned.  
 
In Person Follow -Up Visit or Early Termination  Visit  
Days 5 (± 1 day), 10 (± 1 day)  if applicable , 28 ( + 7 days)  
• Conduct and record the results of a Physical Exam.  
• Review and record concomitant medications (Note: if there have been changes in 
concomitant medications during the study, determine whether the change is due to an AE). 
• Measure and record vital signs (BP, HR, Temp, Resp , SPO2 ). 
• Collect blood samples for:  
o Antibodies to SARS -CoV-2. (Day 28) 
o Biobanking (Day 1 and Day 28)  
o Hematology and clinical chemistry laboratory analyses (Day 5, 10 if applicable, 28)  
o Drug  PK level one hour after dosing (Day 5, if applicable ) 
 
• Assess and record clinical status according to the following study -specific 7 -point 
scale: 
1. Not hospitalized 
2. Hospitalized, not requiring hospital care due to lack of housing  
3. Hospitalized, not requiring supplemental  oxygen  
4. Hospitalized, requiring supplemental  oxygen  
5. Hospitalized, on non- invasive ventilation or high flow oxygen devices  
6. Hospitalized, on  invasive mechanical ventilation or  ECMO  
7. Death  
• Collect oropharyngeal swab for virologic testing (RT -PCR) and resistance analysis.   
• Collect and record adverse events (see Section 8.1.3  for detailed instructions).   
Telehealth Follow -up Visit  
   
Days 120 (±7), 210  (±7), 300  (±7) under Camostat  sub- protocol  
 Days 10 (±1), 35 (+7), 120 (±7), 210  (±7), 300  (±7) under Acebilustat  sub- 
protocol  
• Contact participant via phone for telehealth visit  
 
4.3  Clinical Lab Biomarkers  
• Hematology 
Hemoglobin (Hgb)  Hematocrit (Hct)  
Platelet count  Red blood cell count  
White blood cell count with differential  
COPPS   V9 | 20210921 
 
Confidential   Page 28 of 51 • Chemistry  
Blood Urea Nitrogen (BUN)  Creatinine  
Total bilirubin  Alkaline Phosphatase  
Aspartate transaminase (AST)  Alanine transaminase (ALT)  
Glucose  Lactic dehydrogenase (LDH)  
Total protein  Albumin  
Potassium  Bicarbonate  
Calcium  Sodium  
Urate  Chloride  
 C-reactive protein  
 
 
5. MEASUREMENTS  
For Viral Domain:  
● Primary Outcome Measure Change in  shedding of SARS -CoV-2 virus  through 
day 10 attained from self -collected nasal swab RT -PCR data  after transformation 
using a referenced standard curve. 
● Title:  Change in Viral Shedding  
● Time Frame : 10 days  
● Safety Issue: No 
 
For Clinical Domain:  
Primary Outcome Measure Time from randomization to sustained symptom 
resolution  assessed over a 28- day period . Resolution is defined as  the first day 
where no symptoms are self -reported on all succeeding days through and 
including day 28, not including sense of taste or smell, and defining recovery for 
fatigue and cough as mild or none.  
● Title:  Time -to-sustained -resolution  
● Time Frame : 28 days  
● Safety Issue: No 
 
5.1  Primary and Secondary Outcome measures 
5.1.1 Relevant Subs et 
 
For each interventional therapy comparison, the common control arm will be truncated to include only those who were eligible for the corresponding interventional therapy.  
  
5.1.2 Measurement Definition  
 For Viral Domain: SARS -CoV2 viral RNA levels , through day 10 using self -collected 
nasal swabs,  will be estimated by transforming CT values with a standard Reference 
COPPS   V9 | 20210921 
 
Confidential   Page 29 of 51 curve. We will utilize a generalized linear mixed effects model with parameterization to 
capture the difference in change in viral shedding at day 10 between treatment arms.  To 
generate data from the nasal swabs, we rely on Stanford’s assay, which was issued an 
Emergency Use Authorization (EUA number is EUA200036).  
 For Clinical Domain: Time from randomization to sustained symptom res olution  
assessed over a 28- day period. Resolution is defined as the first day where no 
symptoms are self -reported on all succeeding days through and including day 28, not 
including sense of taste or smell, and defining recovery for fatigue and cough as mil d or 
none. Participants who never experienced resolution will be censored at their last 
survey completion day.  
 
5.1.3 Measurement Methods  
 
 
 
COVID- 19 Outcome Symptom Scale (COSS)  Daily  Questionnaire  
The following questions are about how you feel and how things have been during the past 24 hours  compared to 
your typical health . Give the one answer that comes closest to the way  you have been feeling. Select "None" if you 
have not had this symptom. 
How do you feel compared to yesterday?    I feel better than yesterday  
  I feel the same as yesterday  
  I feel worse than yesterday  
How do you feel compared to last week?    I feel better than last week  
  I feel the same as last week  
  I feel worse than last week  
Cough?  
  None    Mild; just a 
few coughs 
per da y   Mild/ 
Moderate    Moderate; frequent but 
I can tolerate it    Moderate
/ Severe    Severe; I am very uncomfortable  
Shortness of breath  (difficulty breathing) ? 
  None    Mild; just 
short of breath with 
exercise    Mild/ Moderate    Moderate; I get short of breath doing daily activities    Moderate
/ Severe    Severe; I feel I can't get enough air even at rest 
Fatigue  (low energy) ? Please take your oral temperature and 
assess your oxygen saturation with your 
pulse oximeter.  Oral temperature.  ________ F 
Time temperature was obtained.  ________ AM/PM  
Blood oxygen saturation. ________ % 
Did you take a nasal swab today  (study day 1 -10,14,21,28)? Yes       /       No 
Have you taken your study drug as prescribed in the last 24 
hours?   Yes       /       No 
COPPS   V9 | 20210921 
 
Confidential   Page 30 of 51  
  None    Mild; I go 
about  my day 
normally    Mild/ 
Moderate    Moderate; I rest more and restrict activit y   Moderate
/ Severe    Severe; I am staying in bed I'm so tired  
Headache?  
 
  None    Mild; I can 
ignore it    Mild/ 
Moderate    Moderate; I need to 
take medication     Moderate
/ Severe    Severe; it is  markedly 
limiting my life  
Body Ache?  
 
  None    Mild; I can 
ignore the m   Mild/ Moderate    Moderate; I need to restrict some activities    Moderate
/ Severe    Severe; they are 
markedly limiting my 
life 
Joint pain?  
 
  None    Mild; I can ignore them    Mild/ Moderate    Moderate; I need to restrict some activities  
  Moderate
/ Severe    Severe; they are 
markedly limiting my 
life 
Chest pressure?  
 
  None    Mild; I feel it 
occasionally 
but can ignore 
it most of the 
time    Mild/ Moderate    Moderate; I notice it a lot and it limits my activity    Moderate
/ Severe    Severe; I have bad pain and pressure that bothers me most of the time  
Abdominal pain?  
 
  None    Mild; I can ignore it   Mild/ Moderate    Moderate; it is limiting my activities  
  Moderate
/ Severe    Severe; it hurts a lot. 
I may need to see a  
doctor  
Sore Throat ? 
 
  None    Mild; I can ignore it   Mild/ Moderate    Moderate; it is painful to swallow and speak  
  Moderate
/ Severe    Severe; it is limiting 
my ability to swallow 
or speak  
Nasal Congestion?  
 
  None    Mild; I can 
ignore it    Mild/ 
Moderate    Moderate; I notice it a 
lot   Moderate
/ Severe    Severe; it is markedly 
limiting my life  
Chills?  
 
  None    Mild; I can 
ignore it    Mild/ 
Moderate    Moderate; I notice it a 
lot   Moderate
/ Severe    Severe; I am very 
uncomfortable  
Feeling hot or feverish?  
 
  None    Mild; I can 
ignore it   Mild/ 
Moderate    Moderate; I notice it a 
lot   Moderate
/ Severe    Severe; I am very 
uncomfortable  
Runny Nose?  
 
  None    Mild; I can 
ignore it   Mild/ 
Moderate    Moderate; frequent 
but I can tolerate it    Moderate
/ Severe    Severe; I am very uncomfortable  
Taste?  
 
  None    Mild; tastes 
aren’t as 
strong as 
usual    Mild/ 
Moderate    Moderate; I’ve noticed 
I can’t taste certain foods   Moderate
/ Severe    Severe; I cannot taste 
my food at all  
Smell?  
COPPS   V9 | 20210921 
 
Confidential   Page 31 of 51  
  None    Mild; smells 
aren’t as 
strong as 
usual    Mild/ 
Moderate    Moderate; I’ve noticed 
I can’t smell certain 
odors    Moderate
/ Severe    Severe; I cannot 
smell anything at all 
Diarrhea? (loose or watery stools in 24 hours)  
 
  None    Mild; less 
than 3 times    Mild/ 
Moderate    Moderate; 3-6 times    Moderate
/ Severe    Severe; more than 6 
times  
Nausea  (feeling like you want to throw up) ? 
 
  None    Mild; I'm 
eating and 
ignoring it    Mild/ Moderate    Moderate; I don't want 
to eat and can't ignore 
it   Moderate
/ Severe    Severe; I am feeling quite uncomfortable  
Vomiting?  
 
  None    Mild; only 
once or 
occasionally    Mild/ Moderate    Moderate; 3-4 times 
per day    Moderate
/ Severe    Severe; I am having 
trouble keeping food 
down  
How many times have you vomited today?  
 ______  
Do you have a rash?  Yes               /              No  
The rash is (check all that apply):    No rash  
  Covering a small amount of my body  
  Extensive covering of my body  
  Involving the inside of my mouth or lips 
  Itchy  
  Itchy with hives  
In the past 24 hours, have you returned to your usual health (before your 
COVID -19 illness)?  Yes             /                     No 
 
 
5.2  Secondary Outcomes  
1) The primary outcome of the non- assigned domain for an investigational 
therapy (see section 5.1.2 above) . 
2) Time to viral cessation, defined as the time in days from randomization to the 
first of two consecutive negative RT -PCR results of self -collected nasal 
swabs. 
3) Time to first resolution, defined as the first study day where no symptoms  are 
self-reported, not including sense of taste or smell, and defining recovery for 
fatigue and cough as mild or none.  
4) Time to full resolution, defined as the study day where no symptoms are first self-reported.  
5) To evaluate the efficacy of each therapeutic intervention in reducing SARS -
CoV-2 related hospitalizations, ED visits, or death in outpatients with COVID -
19 disease.  
6) To assess development of antibodies to SARS -CoV-2  
COPPS   V9 | 20210921 
 
Confidential   Page 32 of 51 7) To evaluate the safety and tolerability of each therapeutic intervention 
compared with placebo (supportive care).  
a. Adverse events AEs and clinical laboratory tests for systemic safety 
including hematology  and clinical chemistry  
 
 
6. STATISTICAL CONSIDERATIONS  
 
6.1 Statistical Design  
This is an adaptive platform trial with two separate domains and a common control arm.  
Under the Viral Domain we will examine the viral load of a set of investigational therapies; under the Clinical Domain we will examine clinical efficacy of a set of investigational therapies.  The common control arm, only including participants eligible for each treatment,  will be used as a comparator for each investigational therapy (from either 
Domain). Due to logistics of arms beginning and ending and differing eligibility criteria, 
the overall size of the COPPS common control arm will be larger than the subset of the common control arm used to make a comparison for a given investigational therapy.  Each 
Domain is adaptive, such that therapies in the Viral Domain can be dropped for early superior efficacy or therapies can be added based on emerging pre- clinical data; and 
therapies in the Clinical Domain can be dropped for futility or therapies can be added based on emerging pre- clinical data.  
  6.1.1  Randomization 
Participants will be randomized to one of the investigational therapies or the common control group.  A biased coin randomization using  age, sex , receipt of basel ine 
monoclonal antibodies,  and site as inputs will be used to balance the mix of  old/young 
and female/male randomized to each arm. Participants will be randomized with equal probabilities to control and each of the interventions that they are eligible to r eceive. 
That is, participants eligible for the two treatments currently under consideration be 
randomized in a 1:1:1 (2:1 active treatment:placebo) ratio while participants eligible for only one treatment will be randomized in a 1:1 ratio to the treatment and control. If a participant is randomized to placebo, it will be specifically noted what investigational therapies he is eligible to be used as a common control.  
 Treatment arm randomization odds can and will change under COPPS as drugs are introduced and graduated over time. Controls can only be shared for the purpose of answering a particular question about an investigational product if the par ticipant could 
have been randomized to that particular investigational product and they were eligible for that particular investigational product at time of participant enrollment.  
  
COPPS   V9 | 20210921 
 
Confidential   Page 33 of 51 6.2 Descriptive Statistics and Exploratory Data Analysis  
For all arms, descriptive statistics (proportions for categorical variables, means, 
medians, standard deviations and interquartile ranges for continuous variables) will be reported for all key patient variables, including baseline and demographic characteristics, use of  medications, compliance, and study completion status. Data that 
are missing on key patient characteristics and the outcome will be fully described, including any patterns of missingness (i.e., any relationships between missingness of a variable and patient characteristics). A CONSORT diagram displaying the number of patients screened, eligible, and consented along with reasons for ineligibility will be provided. Graphical tools such as histograms, boxplots, and scatterplots will be created to assess quality of data and to display patterns over time.  
 
6.3 Primary Analysis  
 
6.3.1  Analysis Population  
We rely on intention- to-treat principles when addressing the primary objective. 
Specifically, we will evaluate the primary outcome using the intention- to-treat ( ITT) 
population. The intent -to-treat (ITT) population includes all patients randomized to that 
treatment. Patients will be analyzed according to their assigned treatment arm. All efficacy analyses will be completed in the ITT population. The as -treated pop ulation will 
include all randomized patients who received study treatment according to the treatment received. All efficacy analyses will be also be completed in the as -treated population as 
supportive evidence for the primary efficacy analysis.   Control participants will be shared across the treatment arms. Those randomized to 
control will be used as controls in the analyses for the treatments for which they were eligible . Eligibility includes both inclusion/exclusion criteria and if at time of participant 
enrollment,  the treatment was available in the randomization. 
 6.3.2  Analysis Plan  
For the proposed Viral Domain endpoint, we will utilize a generalized linear mixed 
effects model with parameterization to capture the difference in change in viral shedding 
at day 10 between treatment arms.  SARS- CoV2 viral RNA CT values  will be 
transformed  using a standard Reference curve.  The test will be performed at the two-
sided alpha = 0.0 4999 level of significance.  
 The hazard ratio for reduction  in viral shedding will be estimated, along with its 95% 
confidence interval, from a Cox proportional hazards model. If the proportional hazards assumption is not met, we will consider an extended Cox model that relaxes the proportional hazards assumption..  
 For the proposed Clinical Domain endpoint, time to symptom resolution will be 
compared between the treatment and control arms using a two- sided Cox proportional 
hazards model adjusted for age, sex , receipt of baseline receipt of monoclonal 
antibodies,  and site. The test will be performed at the alpha = 0.0 4999 level of 
COPPS   V9 | 20210921 
 
Confidential   Page 34 of 51 significance. The hazard ratio for disease progression will be estimated, along with its 
95% confidence interval, from a Cox proportional hazards model. If the proportional hazards assumption is not met, we will consider an extended Cox model that relaxes 
the proportional hazards assumption. The distribution of disease progression will be estimated using the Kaplan- Meier method, and Kaplan- Meier curves will be presented 
for each treatment arm. Median t ime to  sustained symptom resolution at the end of the 
study period along with 95% confidence intervals will be presented for each treatment arm.  
 
6.4 Secondary Analysis  
 
6.4.1  Analysis Population  
The safety analyses will be performed using the as -treated  population and will include 
all patients who receive study treatment. Patients will be analyzed according to actual treatment received. All safety analyses will be completed in the as -treated population.  
 6.4.2 Analysis  Plan 
There will be no formal adjustment for multiple testing, since this study is a phase 2 trial aimed at efficacy signals detection. Results from all aforementioned analyses will be reported regardless of their significance level and effect size to avoid cherry picking and allow post -hoc adjustment of multiple testing.  
 The frequency of adverse events (AEs) and serious adverse events will be tabulated by type and by treatment arm. AEs will be compared by arm using the Chi -squared test or 
Fisher’s exact test, as appropriate, in the safety analysis set.  
 Clinical laboratory and biomarker results at each time point and change from Baseline will be displayed using summary statistics (n, mean, standard deviation [SD], median, minimum and maximum values) by treatment group. For certain measures, logarithmic normalization or geometric statistics may be evaluated. Values at each time point and 
change from Baseline for weight, and vital sign measurements will be summarized with 
descriptive statistics (n, mean, SD, median, minimum, and maximum) at each time point by treatment group.  
 
6.5  Interim analyses 
There will be one interim analysis in each experimental arm after 50% of the patients 
have been treated.  U sing a Wald test based on the Cox proportional hazards  model 
detailed above, an arm will stop early if the corresponding p- value is less than 
alpha=0.00001 . 
 
6.6 Missing Data Handling  
All efforts will be made to minimize instances of missing data. However, we expect some missing data will occur.  
COPPS   V9 | 20210921 
 
Confidential   Page 35 of 51  
6.6.1 Missing Data Methods – Viral Domain  
Our analyses will assume data are missing at random. Change in viral shedding  will be 
defined by a single participant’s logarithmic base 10 viral load from self-collected nasal 
swab  tests collected on days 1 through 10. We will utilize  the exact times of collection of 
each nasal  swab. Multiple imputation using chained equations will be used to impute 
missing viral load data prior to modeling . Five data sets will be imputed, and imputed 
values will be calculated using non- missing viral load on each of the 13 sample 
collection days  (days 1:10,14,21,28) , treatment arm, age , sex, receipt of baseline 
receipt of monoclonal antibodies, site, and  whether or not a participant was hospitalized. 
A pooled linear mixed effects  model will be fit to log -transformed viral shedding  as a 
function of treatment, age,  sex, receipt of baseline receipt of monoclonal antibodies, and 
site using the 5 imputed data sets. Difference in viral shedding  by treatment arm and 
corresponding 95% confidence intervals will be reported using Rubin’s Rules. The 
difference in change in viral shedding  by treatment arm will also be done after refitting 
the model without participants who were hospitalized to assess sensitivity of results.  
 6.6.2 Missing Data Methods – Clinical Domain  
Analyses will assume data are missing at random. Specifically, if a COSS is only partially completed, resolution is undetermined and considered censored. No te, 
however, that in a previous clinical trial where the COSS was used, we did observe some timepoints where participants did not fill out a COSS, however, we found no cases where COSS was only partially scored.  
For the primary endpoint of time to sustained symptom resolution, any participant who 
dies or drops out prior to having one survey indicating mild to no symptoms will be censored at day 28.  
Sensitivity to a ssumptions regarding missingness will be addressed through sensitivity 
analyses.  
 
Missing da ta will be adjusted as follows:  
• Let m be the last day  with reported data  for patients where m <=28  
• If no symptoms are reported at day m, m -1, and m -2 (total of 48 hours), 
we would classify the patient as having resolved symptoms at day m even 
if m<28.  
• On the other hand, if symptoms are not reported at day m, but symptoms 
are reported at day m -1 or m -2, we would classify the patient as not 
having resolved symptoms at day 28 (censored).  
• If symptoms are reported at day m, we would classify the patient as not 
having resolved symptoms at day 28 (censored), even if m<28 . 
 
COPPS   V9 | 20210921 
 
Confidential   Page 36 of 51 If more than 5% of participants do not have the symptomology data observed (i.e. they 
are right -censored), we will perform a sensitivity analysis to evaluate the robustness of 
our findings to mi ssing data assumptions. In the sensitivity analysis, among those 
missing timing of resolution, we will assume varying proportions (e.g. 25%, 50%) of participants in each arm  who would have resolved symptoms by Day 28. The 
proportions will differ by arm so we can evaluate whether our findings stand if it were true that people who dropped out had symptom resolution earlier in the placebo arm vs the active arm.  
 
 6.6.3 Missing Data Methods – Censoring  
 
Death: Participants who die while in COPPS should be censored at day 28 for the 
clinical domain primary endpoint  and any other time -to-event  secondary endpoint . 
 
Withdrawal: Individuals who withdraw from the study  will be censored at last day of 
observation. Additionally, we will provid e a sensitivity analysis in the case where 
discontinuation from study (not study drug) is differential by treatment arm where participants are censored at Day 28.  Importantly, if participants discontinue from the 
study, we will make every attempt to capture the reason why. Note that ‘withdrawal of 
consent’ or ‘loss to follow up’ are   the only acceptable reasons for withdrawal from the 
study.  
 Hospitalization: Hospital  admission will be censored at day 28 i n the case where a 
patient is hospitalized and discontinues hospital drug, we will still consider them in the study unless they explicitly withdraw from the study, in which case we will record the clinical event and attempt to capture their reason for withdrawal.  
 
6.7  Sample Size Justification  
For the Viral  Domain, the use of a two- sided log rank test at the alpha=0.04999 level of 
significance for the final analysis, 120 patients (60 per arm) will provide 80% power to 
detect an effect size of 0.5 using a two- sample t -test. This leaves alpha=0.00001 to 
check for overwhelming efficacy after 50% of participants have completed 24 hours of 
follow -up. 
 For the Clinical Domain, assuming the use of a two- sided log rank test at the 
alpha=0.04999 level of significance for the final analysis, 78 events will provide 80% power to detect a hazard ratio of 1.91. This leaves alpha=0.00001 to assess overwhelming efficacy after 50% of participants have completed 24 hours of follow -up. 
Assuming the control and treatment arm median time to resolution is 10 and 5 days, respectivel y, a three- month accrual period, a 28 day follow -up period after 
randomization of the last patient, and a drop out of 5% in both the control and treatment arms, it is estimated that the total sample size required to achieve 78 events is 120 (60 patients in each arm).  
 
COPPS   V9 | 20210921 
 
Confidential   Page 37 of 51 6.8 Criteria for stopping enrollment into a treatment  
Participants will be enrolled and randomized to a treatment arm until that treatment is 
stopped due to efficacy as determined by stopping rules pre- specified in that treatment’s 
protocol or if the DSMB recommends that enrollment into the treatment arm be stopped.  
7. DATA AND BIOSPECIMEN COLLECTION, RETENTION AND MONITORING  
The Data Coordinating Center (DCC) housed within Stanford’s Quantitative Sciences Unit (QSU), led by PI Manisha Desai  PhD, will oversee data- related activities including 
data management, monitoring, and analysis.  Stanford will serve at the central laboratory 
and storage facility, responsible for the processing of all assessments of SARS -COV -2 
RNA, such as nasal swabs. Other samples will be collected and stored for concurrent or 
retrospective virologic assessments (e.g., viral RNA in blood, saliva, stool/rectal swabs, 
and lower respiratory tract samples in subjects who become hospitalized; resistance analyses), as feasible . Criteria for resistance monitoring include those who receive an 
antiviral but do not respond.  
 
 
7.1 Data collection instruments  
 
Any paper data (e.g. informed consent documents, screening, and contact information) 
will be maintained in a research chart. The remaining clinical data-- daily 
questionnaires, case record forms (CRFs), and laboratory results --will be entered and 
maintained in Stanford's REDCap database using the minimum number of personal 
identifiers (DOB, dates of visit). Physical copies of laboratory data from point of care 
devices will be stored in a file. Specimen containers and blood tubes will be labeled by the clinical research coordinator only with study ID and date.  Virologic measurements will be entered into a database stored on secured servers and provided from the clinical 
laboratory to the study team.  Biobanked specimens (e.g. PaxGene, plasma, PBMC) will 
be entered into the Stanford Biobank database stored on secure servers.  Stanford will 
serve as the centralized biobank and lab for  processing biospecimens collected across 
all sites.  
The site will be suitably trained on the use of the eCRF and appropriate site personnel 
will be provided electronic signatures.  All site entries will be made in a secured web site 
and the Site Investigator will review the record for completeness.  Upon completion of 
the review, they  will sign electronically in the signature page of the eCRF. The Site 
Investigator or designee will make necessary eCRF corrections.  The investigator must authorize the corrections to the entered data on eCRF.  Specific instructions on use of 
the EDC system and guidelines for data entry and correction will be provided to the sites.   
COPPS   V9 | 20210921 
 
Confidential   Page 38 of 51 7.2 Data management procedures  
  
All subjects will be given a study ID.  Symptom  ques tionnaires and CRFs used at clinic 
visits will be completed by  subjects and or study personnel using only study ID.    
Specimen containers will be labeled by the CRC only with study ID and date, time of 
collection.   Virologic measurements and other biomarkers will be provided back to the 
study team electronically once available and entered into the database.  
  7.3 Data quality control and reporting  
In order to ensure data quality, the study CRC will perform a regular data quality assessments .  All study for ms entered into the data management system will be 
assessed for accuracy with source documents.  In addition, the Data Coordinating Center  will perform weekly reviews of the checks described in the data management 
plan to identify potential data quality issues. The data will be owned by Stanford University.  
 Erroneous data will be communicated to the trial management team and site staff for 
clarification from the source. Data management staff will work with site staff to address 
queries.  
  7.4 Archival of d ata 
Electronic data including all study databases and supporting electronic documentation 
will be archived to cloud- based servers on a daily basis.  
  
7.5 Availability and retention of investigational records  
All data will be kept in secured RedCap and Box servers.  Only the research team will 
have access to the data.    
All records connected with this clinical study will be retained for at least two years 
following the date of an approved marketing application [21 CFR 312.62(c)]; or at least three years from the formal discontinuation the applicable sub protocol study drug, or 
seven years from the end of the study, whichever is longer.  All local laws regarding 
retention of records must also be followed.  Study sites are required to retain all recor ds 
until written notification allowing destruction is received from the Sponsor.  
 
7.6 Subject confidentiality  
Participants will be asked at screening (after the consent is signed) if it is permissible for 
the study staff to contact them via telephone. If so, the participant's preferred telephone 
number will be documented in the research record. Computerized questionnaires via 
REDCap are password protected, encrypted and monitored by Stanford IT.  
COPPS   V9 | 20210921 
 
Confidential   Page 39 of 51   
The following health information related to this study may be used or  disclosed in 
connection with this research study, including, but not  limited to, name and initials, 
address, email, phone number(s), date of  birth, age, sex, race, ethnicity, medical record 
number,  information related to COVID -19 disease, sympto ms, physical  exams, symptoms 
that might relate to medication side effects, vital signs  including temperature and oxygen 
saturation levels  laboratory tests, radioimaging results, pregnancy test and tests of viral  
shedding of Covid- 19 and other viruses, medications received including  study drug, and 
phone call records.  
  
All subjects will be given a sequential study ID. The code for this ID with personal 
identifiers will be maintained in a locked research file accessible only to study personnel.  Only research personnel will have access to the research records. The data will be keyed 
into a secure study website in a coded fashion by the study coordinator.   Any paper 
research documents will be kept in a locked file cabinet with limited access. The study 
coordi nator is the only one that has the key to the locked cabinet where the research 
charts are stored. Laboratory personnel will have access to study specimens.  The data 
is transferred by computer via password protected electronic network. When transferring 
via electronic networks a password protected encrypted computer will be used.  
 
7.7 Audit  
ICH guidelines for GCP require independent inspection of clinical program activities.  Such 
inspections may be performed at any time - before, during and/or after the study.  The site 
Investigator and site study staff are responsible for maintaining the site master file containing all study -related regulatory documentation as outlined by the Sponsor that will 
be suitable for inspection at any time by the Sponsor, its designees, and/or regulatory agencies.  The Investigator understands and agrees to give access to the necessary documentation and files.  
8 ADVERSE EVENT REPORTING AND DOCUMENTATION 
  
8.1 Adverse Events 
Treatment -emergent AEs will be defined as those occurring coincident with start of 
treatment through 28 days post -enrollment . 
Subjects will be instructed to report AEs during the study and staff will query subjects 
regarding AEs throughout the study. The  Site Investigator (and/or designee) must 
document all AEs reported through completion of the Day 28 visit. Any subject who is withdrawn from the study due to an AE shall be followed until the event has resolved or stabilized or  14 days after last study treatment given. The Site Investigator will document 
COPPS   V9 | 20210921 
 
Confidential   Page 40 of 51 available follow -up information on the subject’s source documentation and CRF . Serious 
adverse events (SAEs) potentially related to the study and those possibly unexpected will 
be reported to the local site principal investigator and the Clinical Coordinating Center (CCC) for review.   
 
8.2 Definition of an Adverse Event  
The FDA Safety Guidance, referencing 21CFR312.32(a), defines an Adverse Event as 
follows:  
Adverse event means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related.   
An adverse event (also referred to as an adverse experience) can be any unfavorable and unintended sign (e.g., an abnormal laboratory finding), symptom, or disease tempor ally 
associated with the use of a drug and does not imply any judgment about causality.  An adverse event can arise with any use of the drug (e.g., off -label use, use in combination 
with another drug) and with any route of administration, formulation, or dose, including an overdose.   
Adverse Events are NOT:  
·  Clinical events related to the progression of COVID -19. 
·  Medical or surgical procedures (e.g., surgery, endoscopy, tooth extraction, 
transfusion).  The condition that leads to the procedure is the A E. 
·  Situations where an untoward medical occurrence has not occurred (e.g., 
hospitalization for elective surgery, social and/or convenience admissions).  
8.2.1 Evaluating and Reporting of Adverse Events  
For each adverse event identified  and graded  as severe or life threatening  and felt to be 
possibly, probably or definitely related to study drugs, an adverse event report  form will be 
completed.  In addition, an adverse event form will be completed for all serious adverse events and unexpected events, regardless of severity. An adverse event report form will not be completed for events classified as mild or moderate (unless they are serious or 
unexpected), as mild and moderate symptoms are common and difficult to distinguish from signs and symptoms due t o COVID -19 and other common illnesses .  The Site Investigator 
must follow all AEs until the AE resolves, or until the Investigator and/or the Medical Monitor determine the event is chronic or clinically stable.  If an AE remains unresolved at 
the conclusion of the study, the Site Investigator and Medical Monitor will make a clinical 
assessment to determine whether continued follow -up of the AE is warranted.  All subjects 
who have received at least one exposure to study therapy will be evaluated for safety o f 
study treatment.  
COPPS   V9 | 20210921 
 
Confidential   Page 41 of 51 The Site Investigator should attempt to establish a diagnosis of the event based on signs, 
symptoms and/or other clinical information.  In such cases, the diagnosis should be 
documented as the AE and not the individual signs/symptoms.  
All AEs must be promptly documented on the Adverse Event eCRF and assessed by the 
Investigator.  Details of the event must include the dates of onset and resolution, severity, 
relationship to study drug, seriousness, and whether the event caused the subject to 
withdraw from the study, outcome and timing with regard to administration of the study drug.  
AEs will be categorized using the Division of AIDS Table for Grading the Severity of Adult 
and Pediatric Adverse Events.  
Severity:  Severity should be graded and recorded as follows:  
1. Grade 1 Mild:  No or minimal interference with usual activities; intervention not 
indicated  
2. Grade 2 Moderate:  Greater than minimal interference with usual activity; intervention 
indicated  
3. Grade 3 Severe:  Inability to carry out usual activity, incapacitating; requires 
intervention or hospitalization 
4. Grade 4 Potentially life- threatening:  Inability to perform self -care; intervention 
indicated to prevent permanent impairment, disability or death  
5. Grade 5 Death  
Relationship: The relationship of the Adverse Event to the study drug will be determined 
initially by the Site Investigator, and assessed using the following definitions:  
• Definite: the AE is clearly related to the research procedures  
• Probably : the AE is likely related to the research procedures  
• Possible: the AE may be related to the research procedures  
• Unlikely: the AE is dou btfully related to the research procedures  
• Unrelated: the AE is clearly not related to the research procedures  
• 
Possibly related to participation in the research: There is a reasonable possibility that 
the adverse event, experience, or outcome may have been caused by the procedures 
involved in the research.  
Final determination of relatedness will be made by the Sponsor.  
Expectedness:   
OHRP defines an unexpected AE as any AE occurring in one or more participants 
participating in a research protocol, the nature, severity,  or frequency of which is not 
consistent with either:  
COPPS   V9 | 20210921 
 
Confidential   Page 42 of 51 1) the known or foreseeable risk of AEs associated with the procedures involved in 
the research that are described in a) the protocol -related documents, such as the IRB -
approved research protocol, any applicable investigator brochure, and the current IRB -
approved informed consent document, and b) other relevant sources of information, such 
as product labeling and package inserts; or  
2) the expected natural progression of any underlying disease, disorder, or condition   
of the participant(s) experiencing the AE and the participant’s predisposing r isk factor 
profile fo r the AE.  
These criteria, in addition to good clinical judgment, should be used as a guide for determining the causal assessment.  If it is felt that the event is not related to study drug therapy, then an alternative explanation should be provided.  
8.3 Serious Adverse Events (SAEs)  
All SAEs as defined below and that occur after the first treatment and up to 28  days post -
enrollment  must be reported to the Sponsor as soon as the Site Investigator becomes 
aware of them.  Any SAEs occurring more than 28 days after last study drug administration 
and considered at least possibly drug -related must also be reported.  
8.3.1 Definition of Serious Adverse Events  
An SAE is an AE from this study that results in any of the following outcomes:  
·  Death ( even if caused by COVID -19 all deaths are recorded as SAEs) 
·  Life-threatening situation (subject is at immediate risk of death) 
·  Inpatient hospitalization or prolongation of existing hospitalization  
·  Persistent or significant disability/incapacity  
·  Congenital anomaly/birth defect in the offspring of a subject who received study 
drug 
NOTE: Important medical events that may not result in death, be immediately life-
threatening, or require hospitalization, may be considered an SAE when, based upon appropriate medical judgment, they may jeopardize the subject and  may require medical 
or surgical intervention to prevent one of the outcomes listed in this definition.  
A life -threatening AE is defined as any adverse experience that places the subject in the 
view of the Site Investigator, at immediate risk of death from the event as it occurred.  This 
does not include an event that might have led to death, if it had occurred with greater severity.  
 “Inpatient hospitalization” means the subject has been formally admitted to a hospital for 
medical reasons, for any length of time with a minimum one overnight stay.  Presentation and care within an emergency department does not necessarily constitute an SAE.  
COPPS   V9 | 20210921 
 
Confidential   Page 43 of 51 Complications that occur during hospitalization are AEs.  If a complication prolongs 
hospitalization, it is an SAE.  
8.3.2 SAE Reporting Requirements to the Sponsor  
The procedure for reporting SAEs, regardless of causal relationship , is as follows:  
·  Within 24 hours of the Site Investigator’s knowledge of an SAE, the site must notify 
the Sponsor by phone call to their site monitor, medical monitor or other Sponsor representative. They should also immediately complete the AE eCRF and select “Serious”.  
·  This initial reporting of an SAE should contain as much information as is available 
to the Site Investigator.  Submission of the SAE via the Electronic Data Capture ( EDC) 
should not be delayed in order to collect additional information to complete the f orm. 
·      Follow -up SAE reports may be generated in cases in which additional information 
becomes available.  Hospital records, autopsy reports, and other documents may become 
available and scanned copies can be provided to the Sponsor when applicable.  The 
follow -up SAE report should describe whether the event has resolved or continues, if and 
how it was treated, whether the blind was broken or not, and whether the subject continued or withdrew from study participation.  
·  The Sponsor (or designee) will distribute completed SAE forms, which may be used 
to notify the IRB when applicable, via a secure internet -based document depository.  
·  The Site Investigator should notify the IRB of Serious Adverse Events occurring 
and other adverse reports received from  the Sponsor in accordance with local procedures.  
The Site Investigator must take all therapeutic measures necessary for resolution of the 
SAE.  Any medications necessary for treatment of the SAE must be recorded onto the 
concomitant medication section of the subject’s eCRF.  However, treatment medication should only be recorded in the narrative description section of the SAE form.  
8.4 Suspected Unexpected Serious Adverse Reactions (SUSARs)  
A SUSAR carries specific and time -based reporting requirements for the Sponsor of a 
clinical trial. Thus, after a  Site Investigator reports an SAE, the FDA expects the Sponsor 
will determine whether it meets the definition of a SUSAR.  
A SUSAR is defined according to 3 criteria:  
1.     The AE is deemed a “suspected adverse reaction” if there is a reasonable possibility 
that the study drug caused the AE.  A “reasonable possibility” means there is evidence to suggest a causal relationship between the drug and adverse event.  
2.     The AE is “Serious” if it meets the definition of an SAE provided in section 8.4.5  
3.     The AE is deemed “unexpected” if it is not listed in the Investigator’s Brochure (IB) or if in the IB, has not been reported at the severity observed.  
COPPS   V9 | 20210921 
 
Confidential   Page 44 of 51 In cases where the Sponsor deems a SUSAR has occurred, it must file an IND Safety 
Report with the FDA.  PI will require the assistance and cooperation of the Site Investigator 
and staff to provide accurate and complete information on the subject and observed SAE so that reporting requirements to the FDA can be met.  All SUSAR’s will be additionally 
reported to the DSMB and the IRB.  
8.4.1 Reporting SUSARs to the FDA: IND Safety Reports  
IND safety reports are used to submit reports of SUSARs to the FDA.  There are 2 types of reports:  
· A “15-day report” is used when the reported SAE is a SUSAR and requires that as much 
information as is available to the investigator and the sponsor, be submitted to the FDA in on the appropriate form. For US trials, the appropriate form is the FDA Form 3500A also commonly known as a “MedWatch” form.  
· A “7 -day report” is used when the SUSAR is considered to be fatal or life- threatening.  
The 7 -day and 15- day reports will be submitted by  the Sponsor to the FDA as per  the 
regulatory requirements .   
8.5 Clinica l Laboratory Abnormalities and Other Abnormal Assessments  
Laboratory abnormalities are usually not recorded as AEs unless considered to be clinically significant by the clinician.  An abnormal laboratory result will be considered an AE if it induces clinic al signs or symptoms, if the abnormality is of a degree that requires 
active management (e.g. discontinuation of the study drug, dose modification) or when the event is requiring treatment or other therapeutic intervention (e.g. iron supplements, blood transfusion, etc.). 
The Investigator will evaluate the relationship of any significantly abnormal result to 
protocol treatment and clinical condition, if possible.  All clinically significant abnormal laboratory results will be followed until they return to normal or become stabilized.  
8.6 Handling of Overdose  
An overdose is defined as any dose greater than the highest daily dose included in this document. Any overdose must be recorded. If the overdose is associated with an AE, that AE must be recorded, assessed for seriousness, and reported as an SAE.  
8.7 Management  of Progression of Disease  
Research coordinators will be advised to contact study PI’s with any concerns of 
worsening clinical status.  Specifically, if a patient reports worrisome worsening of 
symptoms (e.g. light -headedness or worsening shortness of breath or new hypoxemia), 
they will be advised to be seen in the Emergency Department. Note that such an 
incident is considered an important clinical event that will be recorded and captured in our electronic data capture system.  
 
COPPS   V9 | 20210921 
 
Confidential   Page 45 of 51 Each sub- protocol may specify continuation of study drug in these cases  (see sub-
protocol appendices) . However , the ultimate decision to continue study drug will be left 
to the admitting team in consultation with study i nvestigators . In all cases, we will 
continue to monitor the patient and encourage retention in the COPPS  trial. Importantly, 
it will be the charge of the DSMB to evaluate such clinical and adverse events so that 
the study may be halted in event of an excess of such events. We will not unblind study 
patients requiring hospitalization unless necessitated by specific circumstances . 
 8.7.1 Liver Function Test Monitoring  
 
Liver function tests (ALT, AST, GGT, alkaline phosphatase [ALP], and total bilirubin)  
will be monitored at  all in person visits. These tests will be monitored for the remainder 
of the study per the Schedule of Events.  
 Subjects with new treatment -emergent ALT, AST or GGT elevations of ≥3 × ULN  
should be followed closely, including repeat confirmatory testing within 48 to 72 hours of  
the initial finding and subsequent close monitoring of these liver enzyme levels, as  
clinically indicated. In subjects in whom confirmatory testing within 48- 72 hours  
confirms elevated ALT, AST or GGT ≥3 × ULN,  prothrombin time (PT) including  
international normalized ratio (INR) and partial thromboplastin time (PTT) should be  
tested.  
 Study drug administration must be permanently discontinued immediately, and the  
medical monitor must be notified if any of the following criteria is met:  
• ALT or AST ≥8 × ULN  
• ALT, AST or GGT ≥5 × ULN for more than 2 weeks  
• ALT or AST ≥3 × ULN, in association with total bilirubin ≥2 × ULN and/or clinical jaundice  
• ALT or AST ≥3 × ULN, in association with symptoms (e.g. nausea, vomiting, fatigue, right upper quadrant abdominal pain)  
 In subjects in whom study drug administration is permanently discontinued, a thorough  
investigation of potential causes for these abnormalities, including alternative etiologies (e.g.,acetaminophen use, other  concomitant medications [including those for CF], viral 
hepatitis, or  alcohol ingestion), should be conducted, and the subject should be followed 
closely for clinical progression/improvement, including close monitoring of the liver 
function tests until levels  normalize or return to baseline. Any subject who discontinues 
from study treatment for  alterations in liver function tests as described above should not 
be withdrawn/discontinued from the study and should complete the remaining study visits.  
 
 
COPPS   V9 | 20210921 
 
Confidential   Page 46 of 51 9 WITHDRAWAL OF  SUBJECTS AND MANAGEMENT OF PROTOCOL 
VIOLATIONS  
  
9.1 Withdrawal of subjects from the study  
  
Participants will be followed until they reach 28 days post -randomization.  Study 
participants will be prematurely withdrawn from the study for: 1) loss to follow up, 
defined as the inability to be located for >7 consecutive days, or 2) withdrawal of 
informed consent . 
 9.2 Removal  of subjects from the study  
The participation of a subject in the study or the administration of treatment may be 
terminated at any time for one of the following reasons:  
• The subject desires to discontinue study treatment.  
• The subject withdraws consent to participate in the study.  
• The subject is unwilling or unable to comply with the safety procedures.  
• The subject is discovered to be pregnant.  
• The subject experiences a medical emergency that necessitates withdrawal.  
• The subject is withdrawn at the discretion of the Investigator for medical reasons or non- compliance.  
 
 
9.3 Protocol Violations  
  
All protocol violations  will be noted and reported to the site’s  Institutional Review Board 
within 5 days of the protocol violation report.  The PI will develop a corrective action plan to present to the IRB for review and approval.  For more information please 
reference the manual of operations for this study.  
10 DATA , SAFETY , & MONITORING 
  The proposed study will conform to rigorous standard monitoring procedures, standardized reporting of adverse events (Adverse Event Report Forms are completed by study coordinators and sent immediately to the investigators), and review of the 
study by Data and Safety Monitoring Boards (DSMB). The sub- protocol PI has primary 
responsibility for the overall conduct of the sub- protocol, including the safety of human 
subjects enrolled in the sub- protocol. The PI will ensure appropriate (1) conduct of the 
informe d consent process (e.g. that informed consent is obtained before proceeding 
with study procedures); (2) enrollment of study subjects; (3) collection and analysis of 
COPPS   V9 | 20210921 
 
Confidential   Page 47 of 51 data; (4) implementation of study procedures to ensure consistent monitoring of 
subjects fo r possible adverse events; (5) review of adverse events and reporting to the 
DSMB and the IRBs; and (6) maintenance of the privacy and confidentiality of study 
subjects. The PI maintains ultimate responsibility for the project and for the safety of study participants.  The PI will be in contact with the research team on a regular basis to 
review the progress of the study and address any human subject issues that occur. 
These discussions may involve adverse event prevention measures, recruiting of appropriat e study subjects, research staff training on protection of human subjects, as 
well as occurrence of adverse events, unexpected incidents, or protocol problems.  
 Due to the restrictions imposed on clinical and hospital visits by the COVID -19 
pandemic, most monitoring activities of this study will be conducted remotely. Monitors will work with the study staff at each site to determine times for “joint” remote or in-
person monitoring – meaning that the monitor and the site study staff will review data 
together  over the telephone.  
 
Monitoring will be conducted according to the applicable ICH and GCP guidelines to 
ensure protocol adherence, quality of data, drug accountability, compliance with 
regulatory requirements and continued adequacy of the investigational site and its facilities.  The site study staff will cooperate in the monitoring process by ensuring the availability of the eCRFs, source documents and other necessary documents at the time of remote monitoring and by prompt attention to any matters brought to their attention 
by the monitor.  
  
10.1 Data and Safety Monitoring Board (DSMB)  
 
We have employed a unique structure for our DSMB. The COPPS trial will have two co-
chairs serving the overarching DSMB, while each sub- protocol will have its own mini -
DSMB  (at least three members plus a chair).  
 The two COPPS DSMB  co-chairs are charged with understanding safety and monitoring 
across the sub -protocols so that issues that occur within any given sub- protocol are 
shared and can inform other sub- protocols. The mini- DSMBs are charged with focused 
safety and monitoring of a given sub- protocol. The COPPS DSMB  kick- off meeting will 
include the two COPPS DSMB co-chairs.  
 A mini- DSMB will be established for each sub- protocol by the study team in cooperation 
with the sponsor to assess at intervals the progress of a clinical trial, safety data, and critical efficacy variables and recommend to the sponsor whether to continue, modify or terminate the trial. While each sub- protocol mini- DSMB will have a chair assigned to 
oversee that sub- protocol, there will be two over-arching DSMB chair s for COPPS. 
Each mini- DSMB will operate according to guidelines documented in their respective 
COPPS   V9 | 20210921 
 
Confidential   Page 48 of 51 mini- DSMB charters. Minutes will be taken to provide a written record of the mini -DSMB 
meetin gs, including interim results; these will be available for review when the trial is 
complete. The COPPS DSMB , composed of mini -DSMBs,  will be a separate entity from 
the Institutional Review Board (IRB). The independence of the DSMBs is intended to 
control the sharing of important comparative information and to protect the integrity of 
the clinical trial from adverse impact resulting from access to trial information. DSMB members will not participate in the study as investigators and will not have conflicts of interest regarding the study or the investigational product. The composition of the mini-
DSMBs will include at minimum:  
  
● DSMB Chair, having experience and expertise in clinical trials  
● Scientist with expertise in viral infectious diseases  
● Biostatisticia n with expertise in clinical trials  
● Additional members may be required with scientific knowledge or clinical 
expertise specific to a sub- protocol.  
  
At a minimum, the mini-DSMBs will meet before randomization begins on the sub-
protocol and to review any interim analysis performed and the clinical trial and safety 
data.  Additionally,  there will be at least one interim analysis for each sub- protocol.  The 
mini- DSMBs will review the study for progress and safety. The PI will provide 
information that will allow the mini- DSMB to review and assess the following:  
● The research protocol, informed consent documents and plans for data safety 
and monitoring;  
● Periodic assessments of data quality and timeliness, participant recruitment, 
accrual and retention, participant risk versus benefit, and other factors that can affect study outcome;  
● Factors external to the study when relevant information, such as scientific or 
therapeutic developments, may have an impact on the safety of the participants 
or the ethics of the trial;  
● Study performance to make recommendations and assist in the resolution of 
problems;  
● The safety of the study participants;  
● The safety and scientific progress of the trial;  
● The continuation, termination or other modifications of the trial based on the observed beneficial or adverse effects of the treatment under study;  
● The confidentiality of the data and the results of monitoring; and  
● Any problems with study conduct, enrollment, sample size and/or data collection.  
  Meetings shall be closed to the public because discussions may address confidential 
patient data. An emergency meeting of the Board may be called at any time should 
COPPS   V9 | 20210921 
 
Confidential   Page 49 of 51 questions of patient safety arise. The DSMB may request the presence of study 
investigators at such meetings.  
  
The sub -protocol PI will distribute study information to the mini- DSMB prior to a 
scheduled meeting. The mini- DSMB may request additions and other modifications to 
this info rmation on a one ‑time or continuing basis. This information will consist of two 
parts: (1) information on study progress such as accrual, baseline characteristics, and 
other general information on study status and (2) any confidential data on study 
outcomes, including safety data. A formal report from the mini- DSMB should be 
supplied to the sub- protocol PI and the pragmatic protocol PI within 3 days of each 
meeting. Each report should conclude with a recommendation to continue, to modify,  or 
to terminate the study. This recommendation should be made by consensus or, when consensus is not achieved, a formal majority vote. A recommendation to terminate the 
study should be transmitted to the PIs and IRBs as rapidly as possible, by immediate telephone and email if sufficiently urgent. In the event of a split vote in favor of 
continuation, a minority report should be contained within the regular DSMB report.   
11. GOVERNANCE   
The trial will be governed by an Executive Committee (EC) that will drive operational 
decisions and a larger Steering Committee (SC) -- comprised of the EC and other 
members including the sub- protocol principal investigators – who will meet on a 
quarterly basis and drive key scientific decisions (Figure 2).   A subset of the SC will form 
the Drug Working Group that will advise the SC on drugs for consideration. An independent data and safety monitoring board (DSMB) will serve as advisory to the SC on issues regarding safety, ethical issues, and prompt dissemination of information important to the public. A Statistical Analysis Committee (SAC) of key unblinded members from the study team will support and inform the DSMB.  More specifically, we 
will have an unblinded team and a blinded team within our Data Coordinating Center (DCC). We rely on standard operating procedures for upholding a firewall throughout database lock to avoid unblinding of results. Both blinded and unblinded teams are involved in research and operational meetings through launch of the study. Upon launch, the blinded and unblinded teams no longer meet and the unblinded team is no longer included in the larger research meetings. Upon launch, only the blinded team is involved in operational decisions and any design changes throughout the study period. The unblinded team that makes up the SAC works closely with the DSMB to provide relevant reports.  
The EC will be the primary decision- making body for day -to-day operations of COPPS. 
The Steering Committee (SC) will drive key scientific decisions and will address high-level trial policy,  protocol and operational issues, and dissemination of findings. In 
particular, the SC will be responsible for introducing additional treatment arms for inclusion in the protocol and successful study completion. The EC will be chaired by Dr. 
COPPS   V9 | 20210921 
 
Confidential   Page 50 of 51 Desai and will meet weekly by teleconference. The SC will meet quarterly and more 
frequently as needed in order to review and have final sign- off on the trial protocol, 
manual of operations, risk -based monitoring plan, data management plan, and 
statistical analysis plan .   
 
 
Figure 2. Governance for COPPS  
 
 
12. ADMINISTRATIVE, ETHICAL, REGULATORY CONSIDERATIONS  
  
12.1 Institutional review board  
This study protocol, all procedures and consent forms, and any subsequent protocol 
amendments must be reviewed and approved by the  site Institutional Review Boards. 
  
12.2 Informed consent form  
All study participants will provide written informed consent for participation in the study 
and future use of biologic specimens.  (Attachment 4 ) 
  
12.3 Discontinuation of the Study  
The Sponsor reserves the right to discontinue the study at any time for any reason.  

COPPS   V9 | 20210921 
 
Confidential   Page 51 of 51  
12.4 Use of Information and Publication 
All information concerning any investigational agent, Sponsor operations, patent 
applications, formulas, manufacturing processes, basic scientific data, formulation, and 
other information supplied by the Sponsor to the Investigator and not previously published is considered confidential and remains the sole property of the Sponsor. The Investigator agrees to use this information only to treat  this patient and will not use it for other purposes 
without written consent of the Sponsor.  
The information obtained in this study will be used by the Sponsor in connection with the 
continued development and, if approved, commercialization of any investigational agent. Thus, Sponsor may disclose such information as required to other clinical Investigators, contractors, and government regulatory agencies.  
Publication or other public presentation of results from this study and related information is subject to the provisions of the Clinical Trial Agreement between Sponsor and the Study Site. 
 
APPENDIX 1: SUB -PROTOCOL S 
Please see sub- protocols included as attachments;  
• Attachment 3.2 contains sub- protocol (camostat mesilate) , version 5  
• Attachment 3.3 contains sub- protocol (acebilustat), version 6 
  